-

01:06:07 PM

LIVE Real Time SNY Stock Market News

SNY - Sanofi

04/07/21 7:00 AM

Nasdaq : SNY

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi's long-term strategy, the company's

RHEA-AI

neutral

03/31/21 6:13 PM

Nasdaq : SNY

FDA approves Sarclisa(R) (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved Sarclisa (R) (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three

RHEA-AI

neutral

01/12/21 8:00 AM

Nasdaq : SNY

Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

Biond Biologics Ltd. ("Biond" or the "Company"), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an

RHEA-AI

very positive

10/21/20 7:00 AM

Nasdaq : SNY

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

Sanofi and the Parkinson's Foundation today announced a new research collaboration to advance the availability of genetic testing and counseling for people living with Parkinson's disease in the U.S. Over the next two years,

RHEA-AI

very positive

09/09/20 7:00 AM

Nasdaq : SNY

Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020

Sanofi Genzyme today announced that new data from across the company's neurology portfolio will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - European Committee for

RHEA-AI

neutral

08/17/20 1:00 AM

Nasdaq : SNY, PRNB

Sanofi to acquire Principia Biopharma

Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of

RHEA-AI

neutral

07/29/20 8:00 AM

Nasdaq : SNY

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation

Sanofi (NASDAQ: SNY; EURONEXT: SAN)Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8751951-sanofi-earnings-results-q2-2020/Q2 2020 sales results reflect the strong performance of Dupixent (R) more than offset by

RHEA-AI

neutral

07/14/20 7:00 AM

Nasdaq : SNY

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

Sanofi and The University of Texas MD Anderson Cancer Center today announced a five-year s...

RHEA-AI

positive

07/09/20 7:00 AM

Nasdaq : SNY

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collabo...

RHEA-AI

neutral

06/19/20 1:51 PM

Nasdaq : SNY, REGN

FDA approves new Dupixent(R) (dupilumab) pre-filled pen designed to support more convenient self-administration

The U.S. Food and Drug Administration (FDA) has approved a 300 mg single-dose pre-...

RHEA-AI

neutral